Literature DB >> 26780449

Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.

Binsah George1, Hagop Kantarjian1, Elias Jabbour1, Nitin Jain1.   

Abstract

Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90-100% of malignant mature B-lymphocyte lineage. The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al. gave the opportunity for heavily pretreated patients with acute lymphoblastic leukemia to go for allogeneic stem cell transplant. Inotuzumab is well-tolerated with the exception of veno-occlusive disease. Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients.

Entities:  

Keywords:  acute lymphoblastic leukemia; antibody drug conjugate; inotuzumab; monoclonal antibody

Mesh：

Substances：

Year:  2016        PMID： 26780449      PMCID： PMC5618942          DOI： 10.2217/imt.15.108

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  46 in total

Review 1.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

Authors:  N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

2.  Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.

Authors:  Pier Paolo Piccaluga; Mario Arpinati; Anna Candoni; Claudio Laterza; Stefania Paolini; Anna Gazzola; Elena Sabattini; Giuseppe Visani; Stefano A Pileri
Journal:  Leuk Lymphoma       Date:  2010-11-15

3.  Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.

Authors:  John F DiJoseph; Maureen M Dougher; Lyka B Kalyandrug; Douglas C Armellino; Erwin R Boghaert; Philip R Hamann; Justin K Moran; Nitin K Damle
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

Review 4.  Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Alan S Wayne; Susan O'Brien
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

5.  Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.

Authors:  Sara Raponi; Maria Stefania De Propris; Stefania Intoppa; Maria Laura Milani; Antonella Vitale; Loredana Elia; Omar Perbellini; Giovanni Pizzolo; Robin Foá; Anna Guarini
Journal:  Leuk Lymphoma       Date:  2011-02-24

6.  Processing of antibodies bound to B-cell lymphomas and other hematological malignancies.

Authors:  R Hanna; G L Ong; M J Mattes
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

7.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

Authors:  Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Elias Jabbour; Partow Kebriaei; Michael Rytting; Sergernne York; Farhad Ravandi; Monica Kwari; Stefan Faderl; Mary Beth Rios; Jorge Cortes; Luis Fayad; Robert Tarnai; Sa A Wang; Richard Champlin; Anjali Advani; Susan O'Brien
Journal:  Lancet Oncol       Date:  2012-02-21       Impact factor: 41.316

8.  Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.

Authors:  J F Dijoseph; M M Dougher; D C Armellino; D Y Evans; N K Damle
Journal:  Leukemia       Date:  2007-07-26       Impact factor: 11.528

9.  Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Authors:  John F DiJoseph; Douglas C Armellino; Erwin R Boghaert; Kiran Khandke; Maureen M Dougher; Latha Sridharan; Arthur Kunz; Philip R Hamann; Boris Gorovits; Chandrasekhar Udata; Justin K Moran; Andrew G Popplewell; Sue Stephens; Philip Frost; Nitin K Damle
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

Review 10.  Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.

Authors:  Nitin Jain; Susan O'Brien; Deborah Thomas; Hagop Kantarjian
Journal:  Front Biosci (Elite Ed)       Date:  2014-01-01
View more
  4 in total

Review 1.  Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.

Authors:  Chelsea Kotch; David Barrett; David T Teachey
Journal:  Expert Rev Clin Immunol       Date:  2019-06-20       Impact factor: 4.473

Review 2.  Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.

Authors:  Delong Liu; Juanjuan Zhao; Yongping Song; Xiaofeng Luo; Ting Yang
Journal:  J Hematol Oncol       Date:  2019-02-08       Impact factor: 17.388

3.  Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

Authors:  Sherry Williams; Miryoung Kim
Journal:  J Adv Pract Oncol       Date:  2018-09-01

Review 4.  Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Authors:  Ilana R Yurkiewicz; Lori Muffly; Michaela Liedtke
Journal:  Drug Des Devel Ther       Date:  2018-07-24       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.